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ABSTRACT
The C/D box scaRNA2 is predicted to guide spe-
cific 20-O-methylation of U2 snRNA. In contrast to
other SCARNA genes, SCARNA2 appears to be
independently transcribed. By transient expression
of SCARNA2-reporter gene constructs, we have
demonstrated that this gene is transcribed by RNA
polymerase II and that the promoter elements
responsible for its transcription are contained
within a 161bp region upstream of the transcription
start site. In mammals, we have identified four cross
species conserved promoter elements, a TATA
motif, an hStaf/ZNF143 binding site and two novel
elements that are required for full promoter activity.
Binding of the human hStaf/ZNF143 transcription
factor to its target sequence is required for
promoter activity, suggesting that hStaf/ZNF143 is
a fundamental regulator of the SCARNA2 gene.
We also showed that RNA polymerase II continues
transcription past the 30-end of the mature RNA,
irrespective of the identity of the Pol II promoter.
The 30-end processing and accumulation are
governed by the sole information contained in the
scaRNA2 encoding region, the maturation occurring
via a particular pathway incompatible with that of
mRNA or snRNA production.
INTRODUCTION
Pseudouridines and 20-O-methylriboses are the most
two common modiﬁcations in ribosomal and small
nuclear RNAs (1,2). In rRNAs and U6 snRNA, they
are performed in the nucleolus by small nucleolar
ribonucleoprotein particles (snoRNPs) (3,4). Box C/D
snoRNPs direct the 20-O-methylation of riboses, while
H/ACA snoRNPs catalyze pseudouridylation (5–8).
Box C/D snoRNPs are composed of a sequence-speciﬁc
guide RNA associated with a set of at least four proteins:
ﬁbrillarin, Nop56, Nop58 and 15.5kDa (4). Each box C/D
snoRNA contains the conserved C, C0, D and D0 box
motifs. Typically, box H/ACA snoRNAs exhibit a
common hairpin–hinge–hairpin–tail structure with the H
motif ANANNA in the single-stranded hinge region, and
the ACA triplet located three nucleotides upstream of the
30-termini (4). H/ACA snoRNAs associate with the four
H/ACA snoRNP proteins, the pseudouridine synthase
dyskerin/Cbf5, Gar1, Nhp2 and Nop10 (9).
U6 snRNA is synthesized by RNA polymerase III
(Pol III) and is modiﬁed and assembled with proteins in
the nucleus. In contrast, U1, U2, U4 and U5 (and likely
U11 and U12) snRNAs are synthesized by RNA
polymerase II (Pol II) and possess a distinct maturation
pathway (10–12). In the nucleus, the Pol II-speciﬁc
snRNAs acquire a monomethyl guanosine (7mG) cap
structure and are extended for at least 250 nucleotides
beyond the 30-end of the mature RNA (13). Stable pre-
snRNAs intermediate bearing a short 30-end extension are
generated by a transcription-linked cleavage event that
requires a cis-acting element called the 30-box (14–16).
After export to the cytoplasm, the pre-snRNA is
assembled with the Sm proteins to form a pre-snRNP.
Binding of the Sm proteins is needed for dimethylation
of 7mG to form the 2,2,7-trimethylguanosine cap struc-
ture and for removal of the 30 trailer. Subsequently,
snRNPs are imported to the nucleoplasm and transiently
accumulate in Cajal bodies (CB) where the snRNAs
undergo speciﬁc 20-O-methylation and pseudouridylation
directed by scaRNAs which accumulate in CB (17–19).
Vertebrate guide scaRNAs contain either one single (C/
D or H/ACA) or two snoRNA boxes. The composite
structures H/ACA-H/ACA, C/D-H/ACA, C/D-C/D or
(C/D-C/D like box) were observed in scaRNAs harboring
two associated boxes. The scaRNAs are synthesized in
the nucleoplasm and a common sequence motif speciﬁ-
cally determines the CB localization of box H/ACA
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was shown to be associated with scaRNAs containing one
single or two snoRNA boxes, the WDR79 binding being
required for CB localization of a scaRNA (21). In
vertebrates, sequences encoding sno- and scaRNAs are
generally located in introns of host genes (22). These
intronic sno/scaRNAs are processed from the spliced
and debranched host introns. U3 and U8 and most
likely U13 snoRNAs, however, are transcribed from inde-
pendent units by RNA polymerase II. In vertebrates, the
basal promoter of the U3 snoRNA genes include an essen-
tial promoter sequence element (PSE) also found in the
basal promoter of snRNA genes (10,23). Associated to the
basal promoter of snRNA and snoRNA genes, the distal
sequence element (DSE) plays a major role in transcrip-
tion eﬃciency (10). The DSE are essentially composed of
two functional submotifs, the octamer and the Staf
Binding Site (SBS), that can reside simultaneously or indi-
vidually (10,24,25). The capped scaRNA2 (mgU2-25/61)
and scaRNA17 (mgU12-22/U4-8) are apparently encoded
in intergenic regions and the presence of conserved motifs
in the upstream region of the genes suggest that scaRNA2
and scaRNA17 are synthesized from independent units.
The capped scaRNA2 contains a C/D box associated to
a C/D like box domain. It is predicted to guide the speciﬁc
20-O-methylation of the U2 snRNA G25 and C61
positions (26). To understand how scaRNA2 synthesis is
controlled, we have cloned the gene and its ﬂanking
regions and demonstrated that 161bp of the 50-ﬂanking
region are suﬃcient for eﬃcient promoter activity. In this
region, we have mapped four essential promoter elements
and identiﬁed hStaf/ZNF143 as a critical transactivator
interacting with the cognate cis-element. Furthermore,
we have shown that transcription of the SCARNA2
gene is governed by RNA polymerase II and continues
beyond the region encoding the mature scaRNA2. The
30-end processing and accumulation of the scaRNA2 are
directed only by sequences within the scaRNA2 encoding
region, contrasting with the mRNA or snRNA production
pathways.
MATERIALS AND METHODS
Reporter constructs
The human SCARNA2 promoter fragment  250/+532
was PCR ampliﬁed from genomic DNA and cloned clock-
wise into pGEMTeasy (Promega) to create SCARNA2
 250/+532. The SCARNA2 promoter fragments  250/
+145,  250/+8,  161/+145,  88/+145 and  25/+145
were PCR ampliﬁed from SCARNA2  250/+532 using
direct and reverse primers incorporating SacI and BamHI
sites, respectively. The PCR products were cloned 50 to the
luciferase reporter gene in the SacI/BamHI cut
promoterless pFLASH1 vector (Synapsis) to generate
SCARNA2  250/+145 Luc, SCARNA2  250/+8 Luc,
SCARNA2  161/+145 Luc, SCARNA2  88/+145 Luc
and SCARNA2  25/+145 Luc. The SCARNA2  250/
+532 maxigene (maxiSCARNA2) was obtained by inser-
tion of a BamH1 site at position +281 of SCARNA2
 250/+532. Substitution mutants giving rise to
constructs Xsub, Ysub, SBSsub and TATA sub are
listed in Figure 1B. Substitution and insertion mutants
were generated with the QuickChange II XL site-
directed mutagenesis kit (Stratagene). The SCARNA2
maxigene with a deletion or an inverted orientation of
the +421 to +532 region (positions relative to the wt
gene) were obtained as follows. A Pst1 site was introduced
at position +421 in maxiSCARNA2 and the resulting
mutant was digested with Pst1 (Pst1cut at +425 and
in the polylinker). Self-ligation yielded the SCARNA2
 250/+421 maxigene 30 (maxiSCARNA230) and
SCARNA2  250/+421 inverted 30 (maxiSCARNA2-
inverted 30). pCMV-maxiSCARNA2 and pU3-
maxiSCARNA2 were generated as follows. A SacII site
was introduced at position  8 of the maxiSCARNA2 con-
taining a Pst1 site at position +421 and the SCARNA2
promoter was swapped with the entire CMV immediate
early promoter from pcDNA3.1(+) (positions +206 to
+855, Invitrogen) or the  324 to  1 fragment of the
U3 snoRNA promoter ampliﬁed from human cell
genomic DNA, to yield pCMV-maxiSCARNA2 and
pU3-maxiSCARNA2, respectively. Swapping of the
SCARNA2 30 ﬂanking sequence in maxiSCARNA2,
pCMV-maxiSCARNA2 and pU3-maxiSCARNA2
(containing a Pst1 at position +421) with the SV40
polyadenylation signal (pA), ampliﬁed by PCR as a
Pst1 fragment from pcDNA3.1(+) (positions +2947
to +3192), yielded maxiSCARNA2-pA, pCMV-
maxiSCARNA2-pA and pU3-maxiSCARNA2-pA,
respectively. MaxiSCARNA2-30boxU1, pCMV-maxiS
CARNA2-30boxU1 and pU3-maxiSCARNA2-30boxU1
were created by swapping the SCARNA2 30 ﬂanking
sequence in maxiSCARNA2, pCMV-maxiSCARNA2
and pU3-maxiSCARNA2 (with a Pst1 at position
+421) digested by Pst1 and Nde1 with the oligonucleotide
ctgcagaGTTTCAAAAGTAGActgtacatatg containing the
U1snRNA 30 box (30-box in capitals). Maxi U6 was
created by inserting the 16bp GACCTCGAGGCGGTT
C sequence at position 87 of the human U6.2 gene.
All constructs were veriﬁed by automated DNA
sequencing.
Transfection and dual luciferase reporter assays
COS-7 cells (8 10
4 cells) were transfected with
Lipofectamine 2000 (Invitrogen). Cells received 500ng of
the SCARNA2 promoter plasmid containing the ﬁreﬂy
luciferase reporter with 50ng of pRL-TK (Promega) as
the renilla luciferase internal control. The total amount
of DNA was kept constant at 800ng with carrier DNA.
After 48h, cells were lysed and the activities of both the
ﬁreﬂy and renilla luciferases were determined with the
dual luciferase assay kit (Promega). A minimum of three
independent transfections were performed in duplicate
and the ﬁreﬂy luciferase activity was normalized to that
of the Renilla luciferase.
Transfection, RNase protection and reverse
transcription assays
HeLa cells (9 10
5 cells) were transfected with
Lipofectamine 2000 with 3.5mg of promoter test plasmid
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scription assays in the presence of a-amanitin, the medium
before transfection was changed to growth medium con-
taining 20mg/ml of a-amanitin and after tranfection the
medium was replaced 19h later by a fresh medium con-
taining 20mg/ml of a-amanitin. Cells were collected after
48h and total RNA was extracted using the TRI-
REAGENT (Euromedex). Synthesis of the internally
labeled antisense RNA probes 1 to 9, complementary
to various parts of the maxiscaRNA2 and variants,
was performed by in vitro transcription with T7 for
probes 1 to 6 (201, 193, 172, 264, 250, 226nt long)
or SP6 for probes 7 to 9 (454, 187 and 187nt
long) polymerases, as described in ref. (28). Probes 1–4
are complementary to positions +207/+299,  14/+71,
+368/+441 and +368/+531 of the maxiSCARNA2 con-
struct, respectively. Probes 5 to 9 are complementary to
positions +283/+460, +368/+495, +307/+760, +307/
+493 and +307/+493 of the maxiSCARNA230,
maxiSCARNA2-inverted30, maxiSCARNA2-pA, maxi
SCARNA2-30boxU1 and pCMV-maxiSCARNA2
constructs, respectively (positions relative to the wt
gene). Before utilization, each probe was puriﬁed on a
6% sequencing gel and further used for RNase protection
assay (RPA) as previously described in refs (28,29).
Brieﬂy, after DNase I treatment, 10mg of total RNA
was annealed with 10
5c.p.m. of probe at 85 C for 5min
and then allowed to hybridize overnight at 45 C. The
unprotected RNA was next digested by incubation with
a mixture of RNases A and T1 and the protected
fragments were separated on a 6% sequencing gel. For
reverse transcription assays, total RNA was analyzed
by primer extension of a labeled oligonucleotide comple-
mentary to positions +88/+104 (wt human U6 gene
numbering). The extended products were separated on a
6% sequencing gel. Results were quantitated with a Fuji
Bioimage Analyzer.
hStaf/ZNF143 preparation and DNA binding assays
Full-length hStaf/ZNF143 was synthesized by in vitro
coupled transcription–translation with the TnT system
(Promega). Fifty microliter reactions were programmed
with 1mg of pSK( )-ZNF143 (30). The various probes
containing the wild-type and mutant versions of the
SBS in the SCARNA2 promoter were obtained by PCR
ampliﬁcation of the  88/+145 region, using
32P-labeled
primers. Gel retardation assays were performed essentially
as described in refs (24,31) with 20 fmol of the labeled
probe in the presence of 2.5mlo r5 ml of programmed
lysate.
ChIP assay and PCR analysis
The ChIP procedure was essentially as described in refs
(32,33). Puriﬁed immunoprecipitated DNA was analyzed
in 25ml PCR reactions in the presence of 3mCi (a-
32P)
dCTP (3000Ci/mmol) with the test primer pair CCTGT
GCTCGGTGGTTTC and GCAGGAGGAGAGCTTTT
CAT, speciﬁc for the SCARNA2 promoter and comple-
mentary to positions  87/ 69 and +228/+247 of the
promoter, respectively. The tRNA
Sec gene test primer
pairs hybridized to sequences  391/ 365 and  205/
 181. For negative controls of the ChIP assay, the PP1
primer pair hybridizing to unique regions lying 2.4kb
upstream of the tRNA
Sec was used. A 1/500 and 1/2000 of
the immunoprecipitated DNA were used in PCR analysis.
Decreasing amounts of input DNA (1/10000, 1/25000
and 1/100000) were used to determine the linear range
of PCR reaction for each primer pair. Cycling parameters
were 95 C for 3min, 35 cycles at 95 C for 30s, 52–72 C
(depending on each primer pair) for 30s, 72 C for 30s and
one cycle at 72 C for 5min.
RESULTS
Biological activities of putative cis-elements in the
human SCARNA2 promoter and identiﬁcation of RNA
polymerase II as the acting polymerase on the
SCARNA2 gene
To identify whether the 50-ﬂanking DNA of the
SCARNA2 gene exhibits promoter activity, various
sequences were fused to a ﬁreﬂy luciferase reporter gene.
As the capped 50-end of the 420nt long scaRNA2 was
previously mapped by primer extension (26), various
constructs containing sequences upstream and down-
stream of the +1 of the scaRNA2 were generated.
Constructs containing progressive 50 truncated portions
of the  250/+145 regions were transiently transfected
into COS-7 cells. The luciferase activity of the resulting
cell extracts was further measured (Figure 1A). Analysis of
the ﬁreﬂy luciferase values, normalized to the activity of
the renilla luciferase control, revealed that similar
promoter activity was observed with fragments containing
161bp or more upstream of the +1 (compare the
luciferase activity of fragments  250/+145 and  161/
+145 in Figure 1A). In contrast, the luciferase activity
of the  88/+145 construct was about 8-fold lower than
that of  161/+145. Construct  25/+145, which contains
only 25bp of the SCARNA2 gene ﬂanking sequence, led
to abrogation of the luciferase activity, showing it is not
suﬃcient on its own for promoter activity (Figure 1A).
Finally, the luciferase activity of construct  250/+8 con-
taining only 8 nucleotides of the transcribed region was
equivalent to that of construct  250/+145 (Figure 1A).
Thus, the 50-ﬂanking sequence of the SCARNA2 gene
possesses a promoter activity and the minimal promoter
sequence can be deﬁned as covering the  161/+8 region.
To identify putative elements in the promoter region of
the SCARNA2 gene, we used the phylogenetic footprint-
ing approach. A multiple alignment was performed with
sequences of the chimpanzee, dog, mouse and rat genomes
that are orthologous to the  250/ 1 region of the human
SCARNA2 gene. This revealed the presence of the four
interspecies conserved elements X, Y, SBS and TATA at
positions  152/ 129,  81/ 72,  70/ 53 and  31/ 26,
respectively (Supplementary Figure S1A and Figure 1B).
Sequence analysis of the region  250/ 1 with the
Matinspector software (34) established that the SBS
element located at positions  70/ 53 matches the consen-
sus binding site for transcription factor hStaf/ZNF143
(Supplementary Figure S1C) (25,35). This analysis did
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Figure 1. Identiﬁcation and functional analysis of the elements in the human SCARNA2 promoter. (A) Detection of promoter activity in the 50-
ﬂanking sequence of the human SCARNA2 gene. Schematic representation of the SCARNA2 constructs fused to a luciferase (Luc) reporter and
their activities in COS-7 cells. For each construct, the length of the sequence upstream and downstream of the +1 is shown to the left and the
luciferase activity to the right. Cells were transiently transfected with the constructs and assayed for luciferase activity. The ﬁreﬂy luciferase activity
was normalized to that of the renilla luciferase provided by co-transfection of the control vector. Data for each construct were plotted as fold-
activation which represents the ratio between the normalized luciferase activity of each reporter construct to that of the empty luciferase vector
(pFLASH1). Data are presented as the mean±SD of three separate experiments. (B) Sequences of the wild-type and mutant X, Y, SBS and TATA
elements of the SCARNA2 promoter. Mutations are highlighted in gray. (C) Contribution of the X, Y, SBS and TATA elements to SCARNA2
promoter activity. Left panel: schematic representation of the SCARNA2 promoter-luciferase (Luc) constructs substituted individually or
simultaneously in the X, Y, SBS and TATA elements. Open and solid boxes represent wild-type and mutant elements, respectively. Right panel:
COS-7 cells were transfected with the reporter constructs and the luciferase activity was normalized to that of the renilla lucifease obtained from the
co-transfected control vector. The normalized luciferase activity of the wild-type construct  250/+145 was arbitrarily set to 100%. Data are
presented as the mean±SD of three separate experiments.
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for the conserved motifs X and Y. Furthermore, the
50-ﬂanking region of the SCARNA2 gene contains no
obvious initiator (Inr) or downstream promoter element
(DPE) in the vicinity of the transcription start site (TSS).
Collectively, this computational analysis revealed the
presence of four conserved motifs in the basal promoter
of the mammalian SCARNA2 gene, constituting putative
elements regulating its expression. Multiple sequence
alignments of the Fugu, Tetraodon, Stickleback,
Medaka and Xenopus tropicalis SCARNA2 promoters
(Supplementary Figure S1B) revealed conservation of
only the SBS and TATA element identiﬁed in the mam-
malian promoters, suggesting their crucial role in
SCARNA2 gene expression.
To evaluate the role of the phylogenetically conserved
elements, we introduced individual mutations into the X,
Y, SBS and TATA elements (Xsub, Ysub, SBSsub and
TATAsub in Figure 1B). Expression of the reporter gene
directed by the mutated SCARNA2 promoters was
monitored by the luciferase activity after transfection
into COS-7 cells. Mutation of the SBS reduced the
SCARNA2 promoter activity to about 30% of the wt
level (Figure 2C, compare wt and SBSsub). These results
provide strong evidence for the presence of a biologically
active SBS in the SCARNA2 promoter. The eﬀect on
transcription activity of substituting the Y element
(Ysub, 73% of the wt level) is of the same order as that
of the TATA element mutation (TATAsub, 79% of the wt
level). In contrast, substitution of the X element reduced
drastically expression from the promoter to 14% of the wt
level (Figure 1C, compare wt and Xsub). Finally, SBSsub
was modiﬁed by sequentially introducing substitutions
into the TATA, Y and X elements (Figure 1B). As
shown in Figure 1C, the simultaneous mutations of the
SBS and TATA element reduced the luciferase activity
to about 20% of the wt level (compare wt, SBSsub and
SBSsub-TATAsub). The reporter activity of the triple
mutant Ysub-SBSsub-TATAsub was of the same order
as that of the double SBSsub-TATAsub mutant,
indicating that the Y element is not essential for
SCARNA2 gene expression. In contrast, introduction of
a fourth mutation by substitution in the X element led to
basal levels of luciferase activity (compare wt, Ysub-
SBSsub-TATAsub and Xsub-Ysub-SBSsub-TATAsub in
Figure 1C). Next, the RPA was used to evaluate the
functionality of the identiﬁed four promoter elements in
the context of the SCARNA2 gene and its 30-ﬂanking
regions. We made use of the SCARNA2 maxigene with
a 6bp insert in the central part of the gene. The 6bp insert
oﬀers the possibility to discriminate the endogenous
scaRNA2 from the product of the transfected gene.
HeLa cells were transfected with the wt maxiSCARNA2,
Xsub maxiSCARNA2, Ysub maxiSCARNA2, SBSsub
maxiSCARNA2, TATAsub maxiSCARNA2 and Xsub-
Ysub-SBSsub-TATAsub maxiSCARNA2 constructs
together with plasmid pa1 as the internal transfection
control (Figure 2A). RNAs were analyzed by RPA of an
antisense RNA probe complementary to region +207/
+299 of the nontranscribed strand maxigene and contain-
ing the 6bp insert (probe 1 in Figure 2A). Results were
normalized to the expression of the a-globin mRNA
included as an internal standard. Analysis of the
mutation eﬀects revealed an expression pattern of
SCARNA2 that is globally similar to that observed with
the SCARNA2 promoter mutants placed in front of a
luciferase reporter gene. The predominant role of the X
and SBS motifs is still observed, with Xsub and SBSsub
expressed at 32% and 48% of the wt level, respectively
(Figure 2B, compare lane 3 with lanes 4 and 6). Next, to
investigate the possible alteration of the TSS by the diﬀer-
ent mutant promoters, we performed an RPA with probe
2 (Figure 2A) that is complementary to a region of the
nontranscribed strand containing the TSS of the
SCARNA2 gene. The presence of three protected
fragments when the wt maxiSCARNA2 gene was used
(fragments b, c and d in Figure 2C, lane 1) suggests the
existence of three diﬀerent TSS. The other analyses
revealed that transcription initiation occurred at exactly
the same position when the Xsub, Ysub and SBSsub
maxiSCARNA2 mutants were used (data not shown).
Surprinsingly, with the TATAsub mutant the relative
alteration in the yield of fragments b, c and d, plus the
detection of a fourth product (product a in Figure 2C,
lane 2) revealed an alteration of the TSS when the
TATA element is mutated.
The characteristics of the SCARNA2 promoter and the
absence of a T strech at the proximity of the mature
scaRNA2 30-end suggest that the SCARNA2 gene is
transcribed by Pol II. To verify this hypothesis, we per-
formed transcription assays with the wt maxiSCARNA2
gene in the presence of plasmid pa1 as the Pol II control
under a-amanitin conditions inhibiting Pol II but not Pol
III transcription (Figure 2D). The extracted RNAs were
analyzed by RPA with probes 1 and anti pa1; the absence
of protected RNA products in the presence of a-amanitin
demonstrated that the SCARNA2 gene is transcribed by
RNA polymerase II (Figure 2D, compare lanes 1, 2 and
3). In an additional control experiment, we showed that
expression of a Pol III maxi U6 gene was unaﬀected under
the same a-amanitin conditions (Figure 2D, compare
lanes 5, 6 and 7). Lastly, the absence of transcriptional
activity of the TATAsub mutant in the presence of
a-amanitin under conditions inhibiting Pol II transcrip-
tion (Figure 2D, lane 4) demonstrated that Pol II is
responsible for the activity of the TATA sub template
(Figure 2B, lane 7).
Taken together, these results indicate that Pol II is the
polymerase acting on the SCARNA2 gene and that there
are four positive regulatory elements in the human
SCARNA2 promoter, the function of the X and SBS
motifs being predominant for full promoter activity.
These results also suggest an important role of the
TATA motif in TSS selection.
The hStaf/ZNF143 transcription factor binds the
cognate element in the human SCARNA2 promoter
Gel mobility shift assays were used to ask whether hStaf/
ZNF143 interacts with the putative SBS located at
positions  70/ 53 in the SCARNA2 promoter. In the
binding assay, the full-length hStaf/ZNF143 was used
374 Nucleic Acids Research, 2010,Vol. 38,No. 2with the
32P-labeled fragment containing the putative SBS.
Figure 3A shows that hStaf/ZNF143 bound to the
SCARNA2 promoter and generated one retarded
complex (Figure 3A, compare lane 1 with lanes 2 and 3).
In contrast, we were unable to detect a retarded complex
with the unprogrammed reticulocyte lysate (compare
lane 1 with lanes 3 and 6 in Figure 3A). The speciﬁcity
of binding was conﬁrmed by competition studies.
As expected, competition by a 1000-fold molar excess of
unlabeled oligonucleotide containing the consensus SBS
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Figure 2. Transcription assays of wild-type and mutated human SCARNA2 gene promoters and polymerase transcribing status of the SCARNA2
gene. (A) Structures of the templates used in the in vivo analyses. The +1 indicates the start of transcription. Open boxes, wild-type elements; solid
boxes, mutant elements. The solid box in the transcribed region represents the 6bp insertion creating the maxigene. Probes 1 and 2 and their
hybridization regions in the nontranscribed strand are indicated (wt gene numbering). (B) In vivo expression of wild-type and mutated gene
promoters. HeLa cells were transfected with the constructs indicated above the lanes together with plamid pa1 as the internal control. RNA
recovered 48h after transfection were analyzed by RNase protection assay with probe 1 and probe anti pa1 complementary to the a-globin
standard. scaRNA2 and a are the protected RNAs derived from the scaRNA2 and pa1 globin internal standard. Results from lanes 1 to 6 and
7 to 9 arose from separate experiments. Normalized transcription activity values: wt, 100%; Xsub, 32±7%; Ysub, 90±9%; SBSsub, 48±10%;
TATAsub, 95±7%. (C) Identiﬁcation of altered TSS of the wt and mutants SCARNA2 promoters. RPA with probe 2 was used to determine
whether transcription of the TATAsub mutant gene initiated at the same position. HeLa cells were transfected with the constructs indicated above
the lanes; a, b, c and d indicate protected fragments. (D) Pol II transcription of the SCARNA2 gene. HeLa cells were transiently transfected with
the constructs indicated above the lanes and treated simultaneously with low a-amanitin concentration (+a-amanitin, lanes 3, 4 and 7) or untreated
( a-amanitin, lanes 2 and 6). Lanes 1–4, RPA performed as in (B) with probe 1 and anti pa1. The lengths of protected fragments are indicated (nt).
Lanes 5–7, primer extension assay performed with RNA isolated from transfected or untransfected cells and a
32P-labeled oligonucleotide comple-
mentary to a region located downstream of the 16bp insertion creating the maxi U6 gene. Data are representative views of experiments performed in
triplicate. Results from lanes 1 to 4 and 5 to 7 arose from separate experiments.
Nucleic AcidsResearch, 2010, Vol.38,No. 2 375(35) abolished complex formation (Figure 3A, compare
lanes 2 and 4). In contrast, an unrelated oligonucleotide
was unable to compete (Figure 3A, lane 5). To demon-
strate that the hStaf/ZNF143 binding pattern was strictly
dependent on the SBS integrity, similar binding assays
were carried out with hStaf/ZNF143 and a promoter
mutant having the  70 CTCCCA  65 sequence in the
SBS substituted by GATATC (24,36,37). Indeed, this
mutation abolished totally formation of the DNA-
protein complex (Figure 3A, lane 8).
To determine whether hStaf/ZNF143 is associated
in vivo with the active SCARNA2 promoter, we performed
a chromatin immunoprecipitation assay in HeLa cells.
After immunoprecipitation with the hStaf/ZNF143
antibody, enrichment of the SCARNA2 promoter was
monitored by semi-quantitative PCR ampliﬁcation using
primers amplifying the SCARNA2 promoter in the region
surrounding the SBS. To conﬁrm the speciﬁcity of
binding, positive and negative controls were performed.
PCR ampliﬁcation of the tRNA
Sec promoter, which
binds hStaf/ZNF143 as well, was used as the positive
control (33). The negative control ampliﬁed a segment
located several kilobasepairs upstream from the tRNA
Sec
transcribed region, which does not harbor any hStaf/
ZNF143 binding site. As a supplementary control, a
similar experiment was performed without antibody. The
SCARNA2 promoter was speciﬁcally immunoprecipitated
by the hStaf/ZNF143 antibody (Figure 3B, compare lanes
1, 2 and 3, 4; the speciﬁc product is indicated by an arrow).
As expected, the positive control with anti-hStaf/ZNF143
yielded a speciﬁc signal of intensity higher than in the no-
antibody control (Figure 3C, compare lanes 1, 2 and 3, 4).
In contrast, no speciﬁc PCR product could be observed
with the PP1 primers amplifying SBS-lacking regions
(Figure 3D, lanes 1–4). We conclude from these
experiments that an SBS resides at positions  70/ 53
and that hStaf/ZNF143 is recruted to the SCARNA2
promoter in living cells.
Transcription of the SCARNA2 gene continues past the
30-end of the mature RNA
The 30-end formation of the independently transcribed
U1–U5 snRNAs, U3, U8 and U13 snoRNAs requires a
cis-acting sequence known as the 30-box, located down-
stream of the 30-end of the mature RNA. Transcription
of the genes encoding these RNAs continues beyond the
30-box in vivo and produces a precursor form that is
not abundant in a steady-state level. The 30-box is not
an eﬃcient transcription terminator but may rather act
as a processing element functioning in the precursor
RNA (13,10,14,16). Scrutiny of the sequence located
at proximity of the 30-end of the mature scaRNA2 did
not show any motif with sequence similarity to the
30-box of Pol II snRNA genes, reading typically
GTTTN0-3AAARN2AGA (38). The 30-end of the
mature scaRNA2 was previously mapped to position
+420 of wt scaRNA2 gene (26). Accumulation and
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Figure 3. Identiﬁcation of an occupied hStaf/ZNF143 transcription factor binding site in the human SCARNA2 promoter. (A) Gel retardation
assays were performed with
32P-labeled promoter fragments encompassing positions  88/+145 of the SCARNA2 promoter and containing the wild-
type SBS sequence (wt probe, lanes 1–6), mutant SBS (SBSsub probe, lanes 7 and 8). In the SBSsub probe, the  70 CTCCCA 65 sequence was
replaced by GATATC. Probes were incubated in the absence (lanes 1 and 7) or presence of hStaf/ZNF143 (2.5ml of programmed reticulocyte lysate
in lanes 2, 4, 5 and 8; 5ml in lane 3). Reactions in lanes 4 and 5 were performed in the presence of a 1000-fold molar excess of unlabeled speciﬁc
competitor (wt SBS) and unspeciﬁc competitor (unspe). Reaction in lane 6 was performed in the presence of 5ml of unprogrammed reticulocyte
lysate. Lanes 1–6 and 7–8 are from separate experiments. (B–D) Immunoprecipitation with hStaf/ZNF143 antibody of the SCARNA2 promoter from
formaldehyde cross-linked chromatin prepared from HeLa cells. DNA fragments recovered from input chromatin, or ChIP assays with anti-hStaf/
ZNF143 or control experiment without antibody, were analyzed by semi-quantitative PCR with speciﬁc primer pairs in the presence of (a 
32P)
dCTP. Lanes 1, 2 and 3, 4: serial dilutions of DNA immunoprecipitated with anti-hStaf/ZNF143 or no antibody, respectively. Lanes 5–7: serial
dilutions of input material to demonstrate that the assays were within the linear range of PCR ampliﬁcation. Lane 8 (C, PCR control): PCR lacking
DNA template. (B) PCR was performed with speciﬁc primer pairs for the human SCARNA2 promoter or (C) for the tRNA
Sec promoter acting as
the positive control. (D) Negative control with the PP1 primer pair targeting a region located upstream of the tRNA
Sec gene and lacking SBS.
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RPA using speciﬁc antisense probes 3 and 4 that map to
the 30-end of the RNA (Figure 4A). Each probe is com-
plementary to the same 30-part of the mature scaRNA2
(positions +368/+420 of the wt gene) and to 21 and 111
nucleotides of downstream regions for probes 3 and 4,
respectively. With both probes, protected fragments
arising from the mature scaRNA2 could be detected
with RNA extracted from untransfected cells (Figure 4B,
lanes 1 and 2). With RNA isolated from maxiSCARNA2
gene transfected cells, probes 3 and 4 detected the mature
scaRNA2 and longer products corresponding to
scaRNA2 precursors (Figure 4B, compare lanes 3 and
4). Due to the low concentration of the endogenous
scaRNA2, the probes detected only the transfected
overexpressed RNA precursors. As expected, the
RNA precursor was undetected in an RPA performed
with RNA isolated from cells transfected with
maxiSCARNA2 gene bearing mutations in the four
promoter elements (Figure 4B, lane 5). To investigate
whether the 30-ﬂanking region of the SCARNA2
contains elements that promote proper 30-end processing
or accumulation, we deleted the genomic sequence
downstream of the mature scaRNA2 30-end in the
maxiSCARNA2 gene to create maxiSCARNA230
(Figure 4A). We also generated construct
maxiSCARNA2-inverted 30 bearing the downstream
region in an inverted orientation (Figure 4A). After cell
transfection, we examined the accumulation and the
presence of an RNA precursor by RPA using RNA
probes complementary to the 30-part of the mature
scaRNA2 and downstream regions (Figure 4A, probes 5
for maxiSCARNA230 and 6 for maxiSCARNA2-
inverted 30). We detected the presence of RNA precursors
and accumulation of properly processed scaRNA2 upon
expression from maxiSCARNA230 (Figure 4C, lane 2,
ratio signal/mock: 2.5) and maxiSCARNA2-inverted 30
(Figure 4D, lane 2, ratio signal/mock: 5). Therefore,
changes in the downstream sequence adjacent to the
mature scaRNA2 30-end had no impact on scaRNA2
accumulation driven by the wt promoter.
The scaRNA2 can be obtained from a variety of Pol II
promoters. 30end processing and accumulation are solely
governed by information in the mature scaRNA2
Monitoring RNA expression from diﬀerent gene contexts
constitutes a powerful approach to obtain insight into the
pathway of transcript maturation. We employed this
strategy to study the scaRNA2 biosynthesis by promoter
exchange or addition of motifs known to be essential for
processing of other RNAs.
In a ﬁrst step, we substituted the scaRNA2 promoter in
construct maxiSCARNA2 with either an mRNA promoter
from the CMV or an snRNA promoter from the U3
snoRNA gene (Figure 4A). The resulting constructs
pCMV-maxiSCARNA2, pU3-maxiSCARNA2 and wt
maxiSCARNA2 were transfected separately into HeLa
cells cells in the presence of pa1 as the internal control
for transfection. After 48h, RNAs were extracted and
analyzed by RPA with three diﬀerent probes (probes 1, 3
and 4 in Figure 4A). RPA with probe 1 complementary to
the central part of the maxiscaRNA revealed that
scaRNA2 is expressed more eﬃciently from pCMV-
maxiSCARNA2 (3.5-fold) and pU3-maxiSCARNA2
(1.45-fold) than from the wt maxiSCARNA2 (Figure 4E,
compare lane 1 with lanes 2 and 3). RPA with probes 3 and
4 revealed that expression from the CMV or the U3
snRNA promoters resulted in the accumulation of
scaRNA2 correctly processed at the 30-end (Figure 4B,
compare lanes 3, 4 with lanes 6, 7 and 8, 9). From these
results, we conclude that scaRNA2 can be produced and
properly 30-end processed from a variety of Pol II
promoters. The RPA performed with probe 5 and RNA
from cells transfected with pCMV-maxiSCARNA230
and pU3-maxiSCARNA230 (harboring deletions down-
stream of the mature scaRNA2 30-end) detected accumu-
lation of correctly processed scaRNA2 (data not shown).
These results conﬁrm that the region downstream of the
mature 30-end is inert in 30-end processing and that only
signals in the mature scaRNA2 direct its processing and
accumulation.
In a second step, we swapped the wild-type
30-ﬂanking sequence in the SCARNA2maxigene with the
mRNA polyadenylation signal (polyA) of the SV40
or the human U1 snRNA 30-box (30-boxU1) down-
stream element (contructs maxiSCARNA2-pA and
maxiSCARNA2-30boxU1 in Figure 5A). Note that the
poly A signal is essential for processing and stability
of mRNAs, while this role in snRNAs is devoted to
the 30-box. The polyA signal and U1 snRNA 30-box
were also introduced into the constructs harboring
the U3 snoRNA or CMV promoters in place of the wt
SCARNA2 promoter (pU3-maxiSCARNA2-pA, pU3-
maxiSCARNA2-30boxU1, pCMV-maxiSCARNA2-pA
and pCMV-maxiSCARNA2-30boxU1 in Figure 5A). The
accumulation and presence of an RNA precursor were
evaluated by RPA using RNA probes complementary to
the central part of the maxiRNA (probe 1) or to the
30-part of the mature scaRNA2 and downstream regions
(Figure 5A, probes 7, 8 and 9). First, RPA results with
probe 1 and anti pa1 as the internal standard showed that
addition of the 30-box U1 or polyA signal in the context of
the wt SCARNA2 promoter reduced the accumulation of
the RNA to 61% and 34% of the wt level, respectively
(Figure 5B, compare lane 1 with lanes 2 and 3). Similarly,
in the context of the U3 snoRNA promoter, the presence
of the U1 snRNA 30-box reduced the accumulation of the
RNA to 75% of the wt level, that obtained with the
addition of the polyA signal being 66% (Figure 5B,
compare lane 4 with lanes 5 and 6). The yield of the
transcribed RNA probed with internal probe 1 is only
slightly aﬀected by the presence of the 30-end processing
elements in the context of the CMV promoter (Figure 5B,
compare lane 7 with lanes 8 and 9). Probes 7, 8 and 9 will
be used to follow formation of the 30- end from constructs
containing the polyA signal, the 30-box U1 or the wt
sequence (Figure 5A). In the RPA experiment with
probe 7 and RNA from untransfected cells, the correctly
processed endogenous 30-end mature scaRNA2 is
indicated by an arrow in Figure 5C (lane 1). The correctly
processed 30-end mature and precursor scaRNA2 are
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Figure 4. The 30 ﬂanking genomic region of the SCARNA2 gene is not required for the processing step and the mature scaRNA2 can be produced
from various Pol II promoters. (A) Structures of the various templates used in the analyses. Probes 1, 3–6 and their hybridization regions in the
nontranscribed strand are indicated (wt gene numbering). (B) Various Pol II promoters produce correctly 30-end processed scaRNA2. HeLa cells
were transfected with the constructs indicated above the lanes. After quantitation, the signal/mock ratios in lanes 3–9 relative to the mature RNA
are: 3.25±0.25, 5±0.3, 1±0.1, 6.7±0.35, 13±0.5, 9.25±0.4, 11±0.25. Results from lane 2 arose from a longer exposure. (C) Deletion of the 30
ﬂanking genomic region of the SCARNA2 gene does not impede production of the mature scaRNA2. Signal/mock ratio relative to the mature RNA
in lane 2: 2.5±0.3 (D) The mature scaRNA2 can be obtained with a construct harboring the 30-ﬂanking region in an inverted orientation. Signal/
mock ratio relative to the mature RNA in lane 2: 3.5±0.5. (E) The U3 snoRNA and CMV promoters are compatible with scaRNA2 production.
RNA extracted from cells transfected with the constructs indicated above the lanes were analyzed by RPA with the indicated probe. pa1: vector used
as the internal transfection control; anti pa1: probe monitoring the RNA produced from the transcribed pa1 gene. scaRNA2 and a: protected RNAs
derived from the scaRNA2 and pa1 globin internal standard. Normalized transcriptional activity values: wt, 100%; pCMV-maxiSCARNA2,
300±25%; pU3-maxiSCARNA2, 145±15%. The lengths of protected fragments are indicated (nt). Data presented in (B–D) are representative
views of experiments performed in triplicate.
378 Nucleic Acids Research, 2010,Vol. 38,No. 2easily detectable using probe 9 with RNA isolated from
cells transfected with pCMV-maxiSCARNA2 (Figure 5C,
lane 4). In contrast, in the presence of the polyA signal or
30-box U1, the transcribed RNA was uncorrectly pro-
cessed and we were unable to detect accumulation
of similar amounts of mature scaRNA2 (compare
Figure 5C, compare lanes 2 and 3 with lane 4). Similar
results were obtained when the pA signal or the 30-box U1
were inserted in the context of the wt or U3snoRNA
driven maxiSCARNA2. However, a lower yield of pro-
ducts was observed (data not shown). Although processing
of the scaRNA2 was independent of the genomic
sequence located 30 to the mature RNA, addition of the
poly A signal or snRNA 30-box reduced signiﬁcantly
the accumulation of scaRNA2 correctly processed at the
30-end.
From these results, we conclude that in contrast
to snRNA genes, the scaRNA2 can be obtained
from various Pol II promoters and without dependence
on 30 elements. In addition, scaRNA2 maturation occurs
via a pathway incompatible with that of mRNAs
or snRNAs.
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Figure 5. Introduction of 30-end processing elements inhibits production of mature scaRNA2. (A) Schematic representation of the structures of the
various constructs used in the assays. (B and C) In vivo expression of the various constructs depicted in (A). HeLa cells were transfected with the
constructs indicated above the lanes. The recovered RNAs were analyzed by RNase protection assay with the indicated probes. pa1: vector used as
the internal transfection control; anti pa1: probe monitoring the RNA produced from the transcribed pa1 gene. scaRNA2 and a: protected RNAs as
in Figure 2. The lengths of protected fragments are indicated (nt). Results from lanes 1–3 and lane 4 in (C) arose from separated experiments. Data
presented are representative views of experiments performed in triplicate. Normalized transcription activity values for lanes 1–9 in (B): lane 1, 100%;
lane 2, 61±25%; lane 3, 34±15%; lane 4, 100 %; lane 5, 75±17%; lane 6, 66±9%; lane 7, 100%; lane 8, 90±9%; lane 9, 85±10%.
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In vertebrates, sequences encoding scaRNAs are generally
located in the introns of their host genes. Intronic
scaRNAs are produced after the splicing step by process-
ing of the debranched intron (19). Here, we demonstrated
that the 161bp region located upstream of the mature
scaRNA2 bears suﬃcient information for Pol II transcrip-
tion of the SCARNA2 gene. This is consistent with the
high-resolution map of the genome wide distribution of
RNA polymerase II which localizes it to a region
covering positions  345 to +40 of the SCARNA2 gene
(39). Furthermore, the present study established that tran-
scription of the human SCARNA2 gene is governed by
four cis-acting elements that are evolutionarily conserved,
a TATA motif, a SBS and two novel, previously
uncharacterized motifs that have been identiﬁed in this
study. The position of the TATA element suggests that
it represents a bona ﬁde TATA binding protein (TBP)
motif, a key basal cis regulatory element shared by Pol
II promoters of protein coding genes and a few RNA
polymerase III promoters. The CTTAAAAG sequence
of the TATA element diverges in the 50-part from the T
ATAAAAG consensus (40). However, structural studies
of TBP–DNA complexes concluded that such a nucleotide
sequence variability does not impair TBP recognition, the
protein being able to accommodate C at position 1 and T
at position 2 of the TATA element (41). Indeed, we
showed that nucleotide substitutions in the TATA
element had only a minor impact on transcription eﬃ-
ciency of the SCARNA2 gene. Besides, substitution in
the TATA sequence led to new TSS, as already observed
for protein-coding genes lacking TATA elements (42). It is
therefore likely that the function of the TATA element is
to ensure correct initiation of transcription as in other Pol
II transcribed genes (42). Motifs X and Y that we
characterized in this study do not correspond to any cis-
acting motif previously identiﬁed. They are only conserved
in mammalian SCARNA2 promoters but are surprisingly
absent in Xenopus and puﬀerﬁsh SCARNA2 genes. This
suggests that these two elements act in a species-speciﬁc
manner. The third cis-acting motif that we identiﬁed is
speciﬁcally recognized by hStaf/ZNF143 which was
found associated to the SCARNA2 promoter in vivo.
Although the Xenopus Staf was originally identiﬁed as
the transcription activator of the tRNA
Sec gene, it also
controls expression of snRNA and snRNA-type genes
transcribed by RNA polymerases II and III (24,25,30).
Furthermore, hStaf/ZNF143 has been reported to
regulate transcription of nine protein-coding gene
(33,36,37). Lastly, a genome-wide analysis led us to
identify 1175 Staf/ZNF143 binding sites distributed in
938 mammalian protein gene promoters (33). This
strongly suggests that hStaf/ZNF143 is involved in the
transcriptional regulation of a very large number of
protein coding genes. The present work extends the role
of hStaf/ZNF143 to the transcription of the scaRNA2
gene which harbors a promoter organization diﬀerent
from that of snRNA and snRNA-type genes.
Interestingly, the SCA2RNA promoter does not contain
the PSE motif which is a key element in the transcription
of snRNA genes (10). Instead, the SCARNA2 gene carries
promoter elements that look like those of protein-coding
genes, as is the case for the telomerase RNA gene (TERC)
and most likely SCARNA17. However, despite this resem-
blance, the organization of the elements is unique within
the promoters of the SCARNA2 and TERC genes (43–
45). The vast majority of snRNA genes are ubiquitously
expressed while, in contrast, expression of most of the
mRNA coding genes is temporally and spatially restricted.
Thus, the presence of an mRNA-type promoter in the
scaRNA2 gene can oﬀer the possibility to also regulate
its expression.
We have not detected elements in the context of the
SCARNA2 gene that can inﬂuence the speciﬁcity of
scaRNA2 synthesis. Furthermore, context elements
known to promote accumulation of mRNA and snRNA
inhibited rather than enhanced production of mature
scaRNA2. Instead of a precursor context dependent
pathway, processing of the scaRNA2 very likely relies
on the integrity of the mature scaRNA2 and in particular
on the C/D-C/D like boxes essential for scaRNP
assembly. We propose, as described for the yeast
snoRNP and human telomerase, that protein association
with the scaRNA2 precursor to form scaRNP is a
prerequesite to 30-end processing of the scaRNA2
(44,46,47). This will be addressed in future investigations.
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